The World's First
Portable Diabetes Screening Device
Recently, AEYE Health announced that its fully automatic AI system, AEYE-DS, received FDA approval, becoming the world's first portable diabetic retinopathy screening device. The system innovatively requires only a single image of one eye, with an imaging success rate exceeding 99%, reducing screening time to just one minute, bringing revolutionary changes to ophthalmic screening. AEYE-DS combines AI and portable technology to provide a cost-effective screening solution, aiding in the prevention of blindness among working-age adults. Diabetic retinopathy, a leading cause of adult blindness, has widespread impact, making early detection and treatment crucial. The widespread adoption of AEYE-DS will significantly increase screening rates, enabling early detection and intervention, offering patients hope for better vision. Its AI model goes beyond traditional diagnostic boundaries, capable of capturing signs of disease from seemingly healthy images, ushering in a new era of precision medicine.
The World's First
Ventricular Assist System with Three Major Certifications
Recently, Abbott's HeartMate 3™ Implantable Left Ventricular Assist System has successfully received approval from the National Medical Products Administration (NMPA), marking a new treatment hope for patients with advanced heart failure in China. As the world’s only left ventricular assist system to simultaneously obtain the NMPA, EU CE, and FDA certifications, the HeartMate 3™ provides patients with a safer and more effective treatment option through its innovative fully magnetically levitated flow technology.The system, through its unique Full MagLev™ technology, achieves stable and gentle handling of blood, significantly reducing the occurrence of complications and enhancing blood compatibility. At the same time, the HeartMate 3™ also features an artificial pulse function that delivers real-time, precise cardiac pulsation, providing patients with a heartbeat experience closer to natural. Additionally, its robust battery life offers patients long-lasting peace of mind.
Since its approval by the FDA in the United States in 2017, the HeartMate 3™ has been implanted in over 33,000 patients worldwide, becoming the preferred treatment option for end-stage heart failure patients. Clinical data shows that this system can significantly extend patient survival, with the longest benefit period reaching up to 15 years. Meanwhile, the latest annual report from STS-Intermacs also confirms the outstanding performance of HeartMate 3™ in improving both short-term and long-term patient survival rates, as well as a significant reduction in critical adverse events.The World's First
Recombinant Botulinum Toxin Type A Approved
In July, Chongqing Yuyan Pharmaceutical Co., Ltd., a subsidiary of MingMed Biotechnology Co., Ltd. based in Guangzhou, announced a historic breakthrough in the medical field with its self-developed injectable recombinant botulinum toxin type A, YY001-002. The product's first indication—adult upper limb muscle spasticity—has been approved by the Chinese regulatory authority to enter clinical trials, marking a global first. Additionally, the company has shown strong performance in the medical aesthetics field, where another recombinant botulinum toxin type A, YY001-001, has completed Phase III clinical trials, with all participants having finished the study.
The world's first marketed
Optical 3D Fluorescence Endoscopic Imaging Device
Recently, the 3D 4K fluorescence endoscopic imaging device and 2D fluorescence endoscopic imaging device independently developed by Beijing Digital Precision successfully received FDA approval. Previously, the 3D 4K fluorescence endoscopic imaging device had already obtained certification from the National Medical Products Administration (NMPA) on December 22, 2022. This is the world's first optical 3D fluorescence endoscopic imaging device to be approved for marketing.
FDA Approved
Revolutionary Breakthrough in Vessel Formation Platform
Recently, Transit Scientific announced that its innovative XO Constrain angioplasty platform has successfully received FDA approval in the United States, specifically for repairing calcified plaques and fibrotic lesions in the peripheral vascular system. The platform offers three configuration options: 10mm, 15mm, and 20mm, each with a working length of 145cm to meet various treatment needs.
The XO Constrain platform is uniquely designed to seamlessly integrate with both compliant and semi-compliant PTA and PTCA balloons, ensuring uniform, atraumatic balloon dilation, vessel scoring, and rewrapping within small or distal vessels. This compatibility extends across a wide range of PTA and PTCA balloons available on the market, with diameters from 1.5mm to 4mm and lengths from 6mm to 20mm, offering physicians significant flexibility and options.
Attract 2 Billion in Financing
Gene Sequencing Emerges as a "Dark Horse"
On July 11, gene sequencing pioneer Element Biosciences announced the successful completion of a Series D funding round, raising over $277 million (approximately RMB 2.011 billion). The funds will accelerate the research, development, and market promotion of its benchtop DNA sequencer AVITI™ and the upcoming AVITI24™ (which integrates cell analysis and multi-omics analysis). This round was led by Wellington Management, with enthusiastic participation from both new and existing investors, including Samsung Electronics, Fidelity, Foresite Capital, T. Rowe Price, and Venrock, bringing Element Biosciences' total funding to over $680 million.
Since its release in March 2022, the AVITI™ sequencer has demonstrated extensive application potential across multiple fields such as RNA gene expression, single-cell RNA sequencing, and whole-exome sequencing due to its superior performance, cost-effectiveness, and high flexibility. It continues to lead innovation in genetic sequencing technology. This round of financing will further solidify Element Biosciences' leading position in the genetic sequencing field, accelerate technological innovation, and bring revolutionary changes to life science research and clinical diagnosis.
Cross-border FDA Approval:
From Dermatology to Cardiovascular
Recently, Pulse Biosciences, a novel bioelectric company, announced that its nanosecond pulsed field ablation system received the FDA Breakthrough Device Designation, causing its stock price to soar over 20% immediately. The company's flagship product, the CellFX system, utilizes nsPFA technology and was originally focused on dermatological treatments such as sebaceous gland hyperplasia and acne. In 2021, CellFX received FDA approval for dermatological procedures and has been successfully commercialized in multiple countries. However, in September last year, Pulse Biosciences announced a strategic shift, halting the sales of CellFX in dermatology to concentrate on broader medical fields like cardiovascular care, expanding its application scope.
CE Approval:
Neuro-navigation Software
Recently，Boston Scientific's Vercise Neural Navigator 5 Software Recently Obtains CE Mark, Signifying Legal Sale and Use in the European Market.As the core software of the Vercise Genus Deep Brain Stimulation (DBS) system, Vercise Neural Navigator 5 integrates STIMVIEW XT technology, specifically designed for the precise treatment of patients with Parkinson's disease, essential tremor, and dystonia.The software, co-developed with Brainlab, significantly enhances programming efficiency by providing real-time visualization of patient brain anatomy, reportedly reducing programming time by up to 56%. As part of Boston Scientific's DBS system, the launch of Vercise Neural Navigator 5 further solidifies the company’s leading position in the field of neuromodulation.
FDA Approval：
Angioplasty Balloon
U.S. medical device company Summa Therapeutics announced that its second-generation Finesse Injectable angioplasty balloon catheter platform has received FDA approval, specifically for percutaneous transluminal angioplasty in peripheral artery disease.This catheter not only delivers high-performance angioplasty but also innovatively integrates a contrast media injection port, enabling a combination of diagnosis and treatment, reducing procedural steps and contrast agent usage, thereby lowering costs.Its unique 0.014-inch guidewire compatibility and design optimizations, such as the adjustment of the injection outlet position and the increase in catheter working length, further enhance surgical efficiency and flexibility.
Summa plans to launch the improved product line globally in the fourth quarter of 2024.FDA Approval Obtained
Alcon Boosts Cataract Business
Recently, Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Cataract System (CS) received FDA 510(k) clearance. Both systems are more efficient than existing products, designed for vitreoretinal surgery and anterior segment procedures respectively, and support laser photocoagulation functionality. Over 200 ophthalmologists globally have participated in testing, with real-world data collection underway to support commercialization in 2025. Alcon plans to submit registration applications to global markets within the year, aiming to obtain the CE mark by early 2025.
Acquisition:
Giant Eyewear Company Acquires Imaging Firm
Global Vision Giant EssilorLuxottica announced that it will acquire 80% of Heidelberg Engineering, a leading German ophthalmic diagnostic technology company. The transaction is expected to be completed in the second half of 2024. With over thirty years of expertise in ophthalmic clinical diagnostics, digital surgery, and medical information technology, Heidelberg Engineering is particularly renowned for its early detection of blinding eye diseases. This acquisition represents another significant move by EssilorLuxottica in the vision care and medical technology sectors, demonstrating its firm commitment to advancing industry standards and improving patient care quality. As an industry giant formed by the powerful merger of Essilor and Luxottica, EssilorLuxottica will continue to provide cutting-edge equipment and solutions to eye care professionals, leading innovation in the vision care industry.
Essilor's acquisition of Heidelberg marks the deep integration of optics and medical technology, heralding global advancements in ophthalmic care solutions. Christoph Schoess, CEO of Heidelberg, looks forward to enhancing image quality, expanding the boundaries of imaging technology, and integrating AI into the HEYEX platform to drive the intelligent development of ophthalmic healthcare.
Approved by NMPA
Abbott Electrophysiology Masterpiece
On July 23, Abbott Medical Devices (Shanghai) Co., Ltd. announced that its self-developed EnSite™ X 3D Cardiac Electrophysiology Mapping System has officially received approval from the National Medical Products Administration (NMPA) for marketing in China, with the registration number GJXZZJ20243070386. The system, based on high-resolution 3D models, integrates precise catheter navigation and potential algorithms to achieve clear visualization of cardiac electrical activity.EnSite™ X not only enhances the precision of electrophysiological mapping but also significantly reduces the exposure time of both doctors and patients to X-rays, lowering the risk of complications in interventional procedures. Its intelligent 3D navigation and automatic data analysis functions enable physicians to efficiently complete complex surgeries, increasing success rates and bringing revolutionary advancements to the field of cardiac electrophysiology treatment.
Acquisition!
3D Printing Leader Boosts Cardiovascular Interventions
Recently, Materialise, a Belgian 3D printing software giant, announced the acquisition of FEops, a cardiac care software developer, aiming to integrate both technologies to optimize cardiac surgery planning. The combination of Materialise's Mimics Planner and FEops' AI predictive simulation technology will create a more comprehensive cardiac surgery planning platform, improving surgical accuracy and efficiency. This move not only strengthens Materialise’s leading position in the cardiovascular field but also provides technical support for manufacturing high-precision medical devices such as 3D-printed heart valves. With the exploration of ultra-lightweight materials like carbon fiber, the future of 3D-printed heart valves looks even more promising.
World's Smallest Interventional Heart Pump
Magenta MeDical recently announced the completion of a $105 million financing round, which will mainly be used to advance the clinical research of its smallest-in-the-world interventional heart pump, Elevate, and to seek FDA approval for use in high-risk percutaneous coronary intervention (HR-PCI).With the global ventricular assist device market expected to grow rapidly at a compound annual growth rate of 17.6%, particularly with the dominance of the left ventricular assist device (LVAD) market, Elevate is facing significant market opportunities.
Elevate's unique technological innovation lies in the perfect combination of its extremely small size and high efficiency. The pump can be delivered to the target area through an 8Fr delivery system, providing an average blood flow of over 5L/min, with peak flow even exceeding 7L/min, far surpassing similar products such as the Impella series.
Source: Siyu Medtech, China Biotechnology Network, The Paper, CCI Cardiovascular Physicians Innovation Club, Instrument Family, Bone Future, etc.
Click to follow "Juyi Technology"Learn about the cutting-edge innovations in global medical devices!
